Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature. 2001, 411: 355-365. 10.1038/35077225.
Article
CAS
PubMed
Google Scholar
Weissman AM: Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol. 2001, 2: 169-178. 10.1038/35056563.
Article
CAS
PubMed
Google Scholar
Hicke L: Getting' down with ubiquitin: turning off cell-surface receptors, transporters and channels. Trends Cell Biol. 1999, 9: 107-112. 10.1016/S0962-8924(98)01491-3.
Article
CAS
PubMed
Google Scholar
Lemmon SK, Traub LM: Sorting in the endosomal system in yeast and animal cells. Curr Opin Cell Biol. 2000, 12: 457-466. 10.1016/S0955-0674(00)00117-4.
Article
CAS
PubMed
Google Scholar
Waterman H, Yarden Y: Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 2001, 490: 142-152. 10.1016/S0014-5793(01)02117-2.
Article
CAS
PubMed
Google Scholar
Hershko A, Ciechanover A: The ubiquitin system. Annu Rev Biochem. 1998, 67: 425-479. 10.1146/annurev.biochem.67.1.425.
Article
CAS
PubMed
Google Scholar
Anderson RG: The caveolae membrane system. Annu Rev Biochem. 1998, 67: 199-225. 10.1146/annurev.biochem.67.1.199.
Article
CAS
PubMed
Google Scholar
Waugh MG, Lawson D, Hsuan JJ: Epidermal growth factor receptor activation is localized within low-buoyant density, non-caveolar membrane domains. Biochem J. 1999, 337: 591-597. 10.1042/0264-6021:3370591.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sorkin A: Endocytosis and intracellular sorting of receptor tyrosine kinases. Front Biosci. 1998, 3: d729-d738.
Article
CAS
Google Scholar
Thien CB, Langdon WY: Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol. 2001, 2: 294-307. 10.1038/35067100.
Article
CAS
PubMed
Google Scholar
Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A, Jovin T, Yarden Y: A mutant EGF-receptor defective in ubiquity-lation and endocytosis unveils a role for Grb2 in negative signaling. Embo J. 2002, 21: 303-313. 10.1093/emboj/21.3.303.
Article
CAS
PubMed
PubMed Central
Google Scholar
Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y: Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999, 4: 1029-1040.
Article
CAS
PubMed
Google Scholar
Feshchenko EA, Langdon WY, Tsygankov AY: Fyn, Yes, and Syk phosphorylation sites in c-Cbl map to the same tyrosine residues that become phosphorylated in activated T cells. J Biol Chem. 1998, 273: 8323-8331. 10.1074/jbc.273.14.8323.
Article
CAS
PubMed
Google Scholar
Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I: Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature. 2002, 416: 183-187. 10.1038/416183a.
Article
CAS
PubMed
Google Scholar
Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, Giordano S: The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature. 2002, 416: 187-190. 10.1038/416187a.
Article
CAS
PubMed
Google Scholar
Watanabe S, Take H, Takeda K, Yu ZX, Iwata N, Kajigaya S: Characterization of the CIN85 adaptor protein and identification of components involved in CIN85 complexes. Biochem Biophys Res Commun. 2000, 278: 167-174. 10.1006/bbrc.2000.3760.
Article
CAS
PubMed
Google Scholar
Take H, Watanabe S, Takeda K, Yu ZX, Iwata N, Kajigaya S: Cloning and characterization of a novel adaptor protein, CIN85, that interacts with c-Cbl. Biochem Biophys Res Commun. 2000, 268: 321-328. 10.1006/bbrc.2000.2147.
Article
CAS
PubMed
Google Scholar
Borinstein SC, Hyatt MA, Sykes VW, Straub RE, Lipkowitz S, Boulter J, Bogler O: SETA is a multifunctional adapter protein with three SH3 domains that binds Grb2, Cbl, and the novel SB1 proteins. Cell Signal. 2000, 12: 769-779. 10.1016/S0898-6568(00)00129-7.
Article
CAS
PubMed
Google Scholar
Govers R, ten Broeke T, van Kerkhof P, Schwartz AL, Strous GJ: Identification of a novel ubiquitin conjugation motif, required for ligand-induced internalization of the growth hormone receptor. Embo J. 1999, 18: 28-36. 10.1093/emboj/18.1.28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Strous GJ, van Kerkhof P, Govers R, Ciechanover A, Schwartz AL: The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. Embo J. 1996, 15: 3806-3812.
CAS
PubMed
PubMed Central
Google Scholar
van Kerkhof P, Govers R, Alves dos Santos CM, Strous GJ: Endocytosis and degradation of the growth hormone receptor are proteasome-dependent. J Biol Chem. 2000, 275: 1575-1580. 10.1074/jbc.275.3.1575.
Article
CAS
PubMed
Google Scholar
de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J: c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route. J Cell Sci. 2001, 114: 2167-2178.
CAS
PubMed
Google Scholar
Polo S, Sigismund S, Faretta M, Guidi M, Capua MR, Bossi G, Chen H, De Camilli P, Di Fiore PP: A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. Nature. 2002, 416: 451-455. 10.1038/416451a.
Article
CAS
PubMed
Google Scholar
Salcini AE, Chen H, Iannolo G, De Camilli P, Di Fiore PP: Epidermal growth factor pathway substrate 15, Eps15. Int J Biochem Cell Biol. 1999, 31: 805-809. 10.1016/S1357-2725(99)00042-4.
Article
CAS
PubMed
Google Scholar
Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH: Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol. 2002, 156: 843-854. 10.1083/jcb.200106056.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden Y, Weissman AM, Lipkowitz S: Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem. 2001, 276: 27677-27684. 10.1074/jbc.M102641200.
Article
CAS
PubMed
Google Scholar
Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y: c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998, 12: 3663-3674.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rotin D, Staub O, Haguenauer-Tsapis R: Ubiquitination and endocytosis of plasma membrane proteins: role of Nedd4/Rsp5p family of ubiquitin-protein ligases. J Membr Biol. 2000, 176: 1-17. 10.1007/s002320001079.
Article
CAS
PubMed
Google Scholar
Carpenter G, Cohen S: 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts. J Cell Biol. 1976, 71: 159-171.
Article
CAS
PubMed
Google Scholar
Swaminathan S, Amerik AY, Hochstrasser M: The Doa4 deubiquitinating enzyme is required for ubiquitin homeostasis in yeast. Mol Biol Cell. 1999, 10: 2583-2594.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bao J, Alroy I, Waterman H, Schejter ED, Brodie C, Gruenberg J, Yarden Y: Threonine phosphoylation diverts internalized EGF-receptors from a degradative pathway to the recycling endosome. J Biol Chem. 2000, 275: 26178-26186. 10.1074/jbc.M002367200.
Article
CAS
PubMed
Google Scholar
Egan JE, Hall AB, Yatsula BA, Bar-Sagi D: The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. Proc Natl Acad Sci USA. 2002, 99: 6041-6046. 10.1073/pnas.052090899.
Article
CAS
PubMed
PubMed Central
Google Scholar
Andoniou CE, Thien CBF, Langdon WY: Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO. 1994, 13: 4515-4523.
CAS
Google Scholar
Bisson SA, Ujack EE, Robbins SM: Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line. Oncogene. 2002, 21: 3677-3687. 10.1038/sj.onc.1205510.
Article
CAS
PubMed
Google Scholar
Calin G, Herlea V, Barbanti-Brodano G, Negrini M: The coding region of the Bloom syndrome BLM gene and of the CBL proto-oncogene is mutated in genetically unstable sporadic gastrointestinal tumors. Cancer Res. 1998, 58: 3777-3781.
CAS
PubMed
Google Scholar
Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, Park M: Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell. 2001, 8: 995-1004. 10.1016/S1097-2765(01)00378-1.
Article
CAS
PubMed
Google Scholar
Mancini A, Koch A, Wilms R, Tamura T: c-Cbl associates directly with the C-terminal tail of the receptor for the macrophage colony-stimulating factor, c-Fms, and down-modulates this receptor but not the viral oncogene v-Fms. J Biol Chem. 2002, 277: 14635-14640. 10.1074/jbc.M109214200.
Article
CAS
PubMed
Google Scholar
Roussel MF, Shurtleff SA, Downing JR, Sherr CJ: A point mutation at tyrosine-809 in the human colony-stimulating factor 1 receptor impairs mitogenesis without abrogating tyrosine kinase activity, association with phosphatidylinositol 3-kinase, or induction of c-fos and junB genes. Proc Natl Acad Sci USA. 1990, 87: 6738-6742.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA: FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA. 1990, 87: 1377-1380.
Article
CAS
PubMed
PubMed Central
Google Scholar
Baker A, Cachia P, Ridge S, McGlynn H, Clarke R, Whittaker J, Jacobs A, Padua RA: FMS mutations in patients following cytotoxic therapy for lymphoma. Leuk Res. 1995, 19: 309-318. 10.1016/0145-2126(94)00128-W.
Article
CAS
PubMed
Google Scholar
Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G: All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem. 1996, 271: 5251-5257. 10.1074/jbc.271.31.18989.
Article
CAS
PubMed
Google Scholar
Pinkas-Kramarski R, Alroy I, Yarden Y: ErbB receptors and EGF-like ligands: Cell lineage determination and oncogenesis through combinatorial signaling. J Mammary Gland Biol Neo-plasia. 1997, 2: 97-107. 10.1023/A:1026343528967.
Article
CAS
Google Scholar
Muthuswamy SK, Gilman M, Brugge JS: Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol. 1999, 19: 6845-6857.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999, 26: 60-70.
CAS
PubMed
Google Scholar
Klapper LN, Waterman H, Sela M, Yarden Y: Tumor-inhibitory antibodies to HER-2/erbB-2 may act by recruiting c-cbl and enhancing ubiquitination of her-2. Cancer Res. 2000, 60: 3384-3388.
CAS
PubMed
Google Scholar
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999, 26: 78-83.
CAS
PubMed
Google Scholar
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.
Article
CAS
PubMed
Google Scholar
Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001, 61: 4892-4900.
CAS
PubMed
Google Scholar
Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989, 9: 1165-1172.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kumar R, Shepard HM, Mendelsohn J: Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol. 1991, 11: 979-986.
Article
CAS
PubMed
PubMed Central
Google Scholar
Blagosklonny MV: Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia. 2002, 16: 455-462. 10.1038/sj.leu.2402415.
Article
CAS
PubMed
Google Scholar
Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 2002, 8 (suppl): S55-S61. 10.1016/S1471-4914(02)02316-X.
Article
CAS
PubMed
Google Scholar
Sepp-Lorenzino L, Ma Z, Lebwohl DE, Vinitsky A, Rosen N: Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J Biol Chem. 1995, 270: 16580-16587. 10.1074/jbc.270.28.16580.
Article
CAS
PubMed
Google Scholar
Mimnaugh EG, Chavany C, Neckers L: Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem. 1996, 271: 22796-22801. 10.1074/jbc.271.9.4974.
Article
CAS
PubMed
Google Scholar
Tikhomirov O, Carpenter G: Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation. J Biol Chem. 2000, 275: 26625-26631. 10.1074/jbc.M003114200.
Article
CAS
PubMed
Google Scholar
Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L: Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem. 2001, 276: 3702-3708. 10.1074/jbc.M006864200.
Article
CAS
PubMed
Google Scholar
Supino-Rosin L, Yoshimura A, Yarden Y, Elazar Z, Neumann D: Intracellular retention and degradation of the epidermal growth factor receptor, two distinct processes mediated by benzoquinone ansamycins. J Biol Chem. 2000, 275: 21850-21855. 10.1074/jbc.M001834200.
Article
CAS
PubMed
Google Scholar
Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, Patterson C, Neckers L, Fry DW, Yarden Y: Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. Embo J. 2002, 21: 2407-2417. 10.1093/emboj/21.10.2407.
Article
CAS
PubMed
PubMed Central
Google Scholar
Labow MA, Baim SB, Shenk T, Levine AJ: Conversion of the lac repressor into an allosterically regulated transcriptional activator for mammalian cells. Mol Cell Biol. 1990, 10: 3343-3356.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cyr DM, Hohfeld J, Patterson C: Protein quality control: U-box-containing E3 ubiquitin ligases join the fold. Trends Biochem Sci. 2002, 27: 368-375. 10.1016/S0968-0004(02)02125-4.
Article
CAS
PubMed
Google Scholar
Pastan I: Targeted therapy of cancer with recombinant immunotoxins. Biochim Biophys Acta. 1997, 1333: C1-C6. 10.1016/S0304-419X(97)00021-8.
CAS
PubMed
Google Scholar
Pastan I, Chaudhary V, FitzGerald DJ: Recombinant toxins as novel therapeutic agents. Annu Rev Biochem. 1992, 61: 331-354. 10.1146/annurev.bi.61.070192.001555.
Article
CAS
PubMed
Google Scholar
Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR: Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA. 1992, 89: 5867-5871.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lorimer IA, Wikstrand CJ, Batra SK, Bigner DD, Pastan I: Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin Cancer Res. 1995, 1: 859-864.
CAS
PubMed
Google Scholar
Mixan B, Cohen BD, Bacus SS, Fell HP, Siegall CB: Betacellulin-Pseudomonas toxin fusion proteins bind but are not cytotoxic to cells expressing HER4; correlation of EGFR for cytotoxic activity. Oncogene. 1998, 16: 1209-1215. 10.1038/sj.onc.1201632.
Article
CAS
PubMed
Google Scholar
Dean GS, Pusztai L, Xu FJ, O'Briant K, DeSombre K, Conaway M, Boyer CM, Mendelsohn J, Bast RC: Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clin Cancer Res. 1998, 4: 2545-2550.
CAS
PubMed
Google Scholar
Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, Pastan I: Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res. 1999, 5: 2311-2315.
CAS
PubMed
Google Scholar